|
|
Post by boca1girl on Jun 7, 2021 8:51:31 GMT -5
I remember semaglutide was on the potential product pipeline in the past with related patents. On Friday, the FDA announced that Wegovy (semaglutide) had been approved for chronic weight management in adults who are either obese or overweight, and who have at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol). The therapy, which is expected to be launched by Novo Nordisk in the US later this month, comes in the form of a once-weekly injection, delivering the hormone glucagon-like peptide-1 (GLP-1) that makes recipients feel fuller, helping them to subsequently eat less. www.sciencealert.com/game-changer-treatment-is-first-new-weight-loss-drug-approved-by-the-fda-in-years |
|
|
|
Post by peppy on Jun 7, 2021 9:10:23 GMT -5
I remember semaglutide was on the potential product pipeline in the past with related patents. On Friday, the FDA announced that Wegovy (semaglutide) had been approved for chronic weight management in adults who are either obese or overweight, and who have at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol). The therapy, which is expected to be launched by Novo Nordisk in the US later this month, comes in the form of a once-weekly injection, delivering the hormone glucagon-like peptide-1 (GLP-1) that makes recipients feel fuller, helping them to subsequently eat less.
www.sciencealert.com/game-changer-treatment-is-first-new-weight-loss-drug-approved-by-the-fda-in-yearsYes, semaglutide on the pipeline list. Looky here, OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C- cell tumors has not been determined (5.1, 13.1). OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (4, 5.1). Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.
www.sciencealert.com/game-changer-treatment-is-first-new-weight-loss-drug-approved-by-the-fda-in-years |
|
|
|
Post by sportsrancho on Jun 7, 2021 12:27:34 GMT -5
You don’t over eat because you’re hungry ..so good luck with that.
|
|
|
|
Post by boca1girl on Jun 7, 2021 14:37:56 GMT -5
You don’t over eat because you’re hungry ..so good luck with that. I agree with your statement. Overeating seems to be caused more by your mental state or emotions. But if you feel really full, like you can’t eat another bite, that may make a difference. They ran the clinical trials and the drug was proven to work compared to placebo. |
|
